Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Aldoxorubicin + Dactolisib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Aldoxorubicin | INNO-206|Doxorubicin-EMCH | Chemotherapy - Anthracycline 13 | Aldoxorubicin (Doxorubicin-EMCH) is a derivative prodrug of doxorubicin that is converted to free doxorubicin within the acidic environment within tumors, and once converted, doxorubicin intercalates DNA, inhibits DNA synthesis and induces apoptosis (PMID: 30936721). | |
Dactolisib | NVP-BEZ235|BEZ235 | ATR Inhibitor 16 mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | Dactolisib (BEZ235) inhibits PI3K kinase, mTOR kinase, and ATR, which may result in tumor cell apoptosis and growth inhibition of tumor cells (PMID: 18606717, PMID: 21552262, PMID: 32088816). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|